# A Study About How ASP5354 Affects the Body in Healthy Adults and in Adults Whose Kidneys do Not Work Well

> **NCT05495581** · PHASE1 · COMPLETED · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 28 (actual)

## Conditions studied

- Healthy Volunteers
- Renal Impairment

## Interventions

- **DRUG:** pudexacianinium chloride

## Key facts

- **NCT ID:** NCT05495581
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-25
- **Primary completion:** 2023-04-27
- **Final completion:** 2023-05-08
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2024-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05495581

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05495581, "A Study About How ASP5354 Affects the Body in Healthy Adults and in Adults Whose Kidneys do Not Work Well". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05495581. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*